STRICT SIGNED
SN: The first blood biomarker to accurately STratify mortality Risk In patients with Cardiac arrhyTmia
Total Cost €
0EC-Contrib. €
0Partnership
0Views
0STRICT project word cloud
Explore the words cloud of the STRICT project. It provides you a very rough idea of what is the project "STRICT" about.
Project "STRICT" data sheet
The following table provides information about the project.
| Coordinator |
CARDINOR AS
Organization address contact info |
| Coordinator Country | Norway [NO] |
| Total cost | 119˙805 € |
| EC max contribution | 119˙805 € (100%) |
| Programme |
1. H2020-EU.2.3.2.2. (Enhancing the innovation capacity of SMEs) |
| Code Call | H2020-INNOSUP-2019-02 |
| Funding Scheme | CSA |
| Starting year | 2019 |
| Duration (year-month-day) | from 2019-12-15 to 2020-12-14 |
Partnership
Take a look of project's partnership.
| # | ||||
|---|---|---|---|---|
| 1 | CARDINOR AS | NO (OSLO) | coordinator | 119˙805.00 |
Map
Project objective
Cardiovascular disease (CVD) is the no. 1 killer worldwide. 25% of all CVD mortality is caused by ventricular arrhythmias that lead to sudden cardiac death (SCD). The diagnosis of arrhythmias is difficult but crucial for accurate decision-making and patient survival. To assess the patient’s status, cardiologists currently ask: physical exams, some cardiac biomarkers data, an ECG (which may detect an arrythmia) and an echocardiogram to measure the blood ejection from the left ventricle (LVEF), since there is a correlation between LVEF and risk of ventricular arrhythmias. If LVEF is < 35%, the patient is eligible for implantable cardioverter-defibrillator (ICD) surgery, which costs at least 20K€. Still, around 51 % of victims of SCD have normal LVEF. In addition, 67% of all implemented ICDs are never activated because those patients were (unknowingly) at low-risk for arrhythmias, which represents a 1.3B€ overtreatment cost / year in the EU alone. CardiNor is bringing to market a new in vitro diagnostic (IVD) test to measure blood levels of Secretoneurin (SN), a globally patented biomarker and the only one shown to be specifically linked to ventricular arrhythmias. With SN data, cardiologists will be able to stratify patients according to their risk as well as to pinpoint high-risk patients not identified by the current diagnostic regime, thus reducing health burden costs and saving lives. CardiNor needs the SME Innovation Associate Programme to boost R&D activities within test maturation and effectively take it to TRL8. Currently, we do not have in-house expertise in biomedical device development or quality assurance. Therefore, we are looking to recruit an Innovation Associate. Acquiring these skills is important for CardiNor to maintain competitive advantage over coming years, positioning our company to high growth in the global CVD biomarkers market.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "STRICT" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "STRICT" are provided by the European Opendata Portal: CORDIS opendata.